背景:Lisdexamfetaminedimesylate(LDX)已证明治疗暴食症(BED)的安全性和有效性。然而,到目前为止,试验尚未纳入患有精神疾病的参与者.这项研究探讨了LDX如何影响饮食失调精神病理学,床常见精神病合并症的症状(ADHD,抑郁症,焦虑),和生活的心理素质,中度至重度卧床的人。
方法:这些是在41名成年人(18-40岁)中进行的开放标签LDX试验的二级分析。参与者接受LDX滴定至50或70mg。在基线和8周随访时进行临床评估和自我报告问卷。
结果:LDX治疗8周后,进食障碍的精神病理学和心理生活质量得到改善。抑郁症没有明显的群体水平变化,观察焦虑或ADHD严重程度评分。然而,在抑郁和ADHD症状升高的小亚群中,大多数人的抑郁和注意力不集中症状严重程度降低,分别。
结论:我们提供了概念证明证据,证明LDX可能为BED患者提供更广泛的心理益处,除了降低他们的频率。临床医生应密切监测LDX对焦虑的影响。早期迹象表明,LDX可以有效地用于BED患者,有或没有共存的精神病,然而,在高度复杂的病例中,耐受性可能较低。
背景:澳大利亚和新西兰临床试验注册中心(anzctr.org。au)#ACTRN12618000623291。
Lisdexamfetaminedimesylate(LDX)已被证明可以降低暴食障碍(BED)患者的暴食频率。然而,关于LDX如何影响常见合并病症的症状知之甚少(ADHD,抑郁症,焦虑)和心理健康。在这项研究中,41名BED患者接受了为期8周的LDX疗程,并在治疗前后监测其症状。总的来说,人们在饮食失调精神病理学和心理生活质量方面有了很大的改善。对于那些抑郁和多动症程度较高的人来说,LDX有改善抑郁症状和注意力不集中的症状严重程度的额外好处,分别。LDX对焦虑症状的影响似乎更复杂,在治疗过程中,有相同比例的人经历焦虑的减少或增加。那些在治疗期间焦虑减轻的人倾向于同时减少暴饮暴食的频率。这项研究提供了初步证据,对于患有BED的人来说,LDX可能有效改善进食障碍精神病理学和心理健康的共同发生症状,以及潜在的多动症和抑郁症状。需要在更大的样本中进行更多的研究来验证这些发现。
BACKGROUND: Lisdexamfetamine dimesylate (LDX) has demonstrated safety and efficacy for treatment of Binge Eating Disorder (BED). However, to date, trials have not included participants with co-occurring psychiatric disorders. This study explores how LDX affects eating disorder psychopathology, symptoms of common psychiatric comorbidities of BED (ADHD, depression, anxiety), and psychological quality of life, in people with moderate to severe BED.
METHODS: These are secondary analyses of an open-label LDX trial conducted in 41 adults (18-40 years) over eight-weeks. Participants received LDX titrated to 50 or 70 mg. Clinical assessments and self-report questionnaires were conducted at baseline and 8-week follow-up.
RESULTS: Eating disorder psychopathology and psychological quality of life improved after 8-weeks of LDX. No significant group-level changes in depression, anxiety or ADHD severity scores were observed. However, the majority within the small subsets with elevated depression and ADHD symptoms experienced reduced depressive and inattentive symptom severity, respectively.
CONCLUSIONS: We provide proof-of-concept evidence that LDX may provide broader psychological benefits to individuals with BED, beyond reducing their BE frequency. Effects of LDX on anxiety should be monitored closely by clinicians. Early indications suggest that LDX may be effectively used in people with BED, with and without co-occurring psychiatric conditions, however tolerability may be lower in highly complex cases.
BACKGROUND: Australian and New Zealand Clinical Trials Registry (anzctr.org.au) #ACTRN12618000623291.
Lisdexamfetamine dimesylate (LDX) has been shown to reduce binge eating frequency among those with Binge Eating Disorder (BED). However, little is known about how LDX affects symptoms of common co-occurring conditions (ADHD, depression, anxiety) and mental health more broadly. In this study, 41 people with BED received an 8-week course of LDX and their symptoms were monitored before and after treatment. Overall, people experienced a robust improvement in eating disorder psychopathology and psychological quality of life. For those with higher levels of depression and ADHD, LDX had the additional benefit of improving depressive symptoms and inattentive symptom severity, respectively. The effect of LDX on anxiety symptoms appears to be more complex, with an equal proportion of people experiencing a decrease or an increase in anxiety over the course of treatment. Those who experienced reductions in anxiety during treatment tended to have greater concurrent reductions in binge eating frequency. This study provides preliminary evidence that for people with BED, LDX may be effective at improving co-occurring symptoms of eating disorder psychopathology and psychological well-being, and potentially ADHD and depression symptoms when present at an elevated level. More research is needed among a larger sample to verify these findings.